Literature DB >> 23319061

[Interferon alpha 2b for treatment of conjunctival melanoma: a case report].

C Schumacher1, C Heinz, P Lommatzsch, A Lommatzsch, J Koch.   

Abstract

A 71-year-old female patient with a status following multiple conjunctival excisions, histopathologically confirmed conjunctival melanoma (CMM) and also multiple therapy with mitomycin C presented with progressive conjunctival pigmentation. Treatment was carried out with local interferon α2b administration four or five times daily for several months. The lesion showed regression and lost pigmentation without any side effects.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23319061     DOI： 10.1007/s00347-012-2736-3

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  12 in total

1.  Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations.

Authors:  H Demirci; S A McCormick; P T Finger
Journal:  Arch Ophthalmol       Date:  2000-07

2.  Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients.

Authors:  C L Shields; J A Shields; K Gündüz; J Cater; G V Mercado; N Gross; B Lally
Journal:  Arch Ophthalmol       Date:  2000-11

3.  Long-term follow-up of patients with conjunctival melanoma.

Authors:  Cornelia Werschnik; Peter K Lommatzsch
Journal:  Am J Clin Oncol       Date:  2002-06       Impact factor: 2.339

4.  Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience.

Authors:  Madhavi Kurli; Paul T Finger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-07       Impact factor: 3.117

5.  Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex.

Authors:  Paul T Finger; Ragui W Sedeek; Kimberly J Chin
Journal:  Am J Ophthalmol       Date:  2007-11-05       Impact factor: 5.258

6.  Topical treatment options for conjunctival neoplasms.

Authors:  Jonathan W Kim; David H Abramson
Journal:  Clin Ophthalmol       Date:  2008-09

7.  Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases.

Authors:  P De Potter; C L Shields; J A Shields; H Menduke
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

8.  Interferon alpha for the treatment of melanocytic conjunctival lesions.

Authors:  Tina Rike Herold; Christoph Hintschich
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-09-15       Impact factor: 3.117

9.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Authors:  J M Kirkwood; M H Strawderman; M S Ernstoff; T J Smith; E C Borden; R H Blum
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

10.  Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia.

Authors:  R R Vann; C L Karp
Journal:  Ophthalmology       Date:  1999-01       Impact factor: 12.079
View more
  2 in total

1.  Real-life data of adjuvant IFN-α2b and MMC in conjunctival melanocytic lesions.

Authors:  Simone Nuessle; Claudia Auw-Haedrich; Jana Jiang; Daniel Boehringer; Thomas Reinhard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-10-18       Impact factor: 3.535

Review 2.  [Adjuvant therapy and interdisciplinary follow-up care of conjunctival melanoma].

Authors:  L M Heindl; K R Koch; M Schlaak; C Mauch; C Cursiefen
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.